The turnover of the company from the activities in the quarter grew by 15% to RS 5,842 Crore versus RS 5,086 Crore in Q1FY25.
The pat was 11% higher on a successive base versus RS 390 Crore in Q4FY25, while the top line rose by 4.5% compared to RS 5,592 reported by the company in Q4FY25.
The income was announced after market hours and Apollo Hospitals shares ended with Minor Downtick on RS 7,253 on the NSE.
Segment income
The company earned its income from health care, retail health & diagnostics, digital health and pharmacy distribution and also as other income.
– The turnover of healthcare services was RS 2,974 Crore in Q1FY26 versus RS 2,843 Crore in Q4FY25 and RS 2,654 Crore in Q1FY25.
– Retail Health & Diagnostics Revenue amounted to RS 435 Crore in Q1FY26 versus RS 394 Crore in Q4FY25 and RS 366 Crore in Q1FY25.
– The turnover of digital health and pharmacy distribution amounted to RS 2.472 crore in Q1FY26 versus RS 2,376 crore in Q4FY25 and RS 2,082 crore in Q1FY25.
Read also: Nykaa Q1 Results: cons Pat radiates 79% yoj to RS 24 crore, the turnover jumps 23%
Q1 expenditure
The costs of the company were reported on RS 5.313 CRORE, based on a yo -yo and qoq basis. In the previous quarter, Apollo hospitals had reported editions of RS 5,148 Crore while RS 4,704 Crore in the period of the year ago. The costs were made on material used by the hospital, purchases of stock-in-trade, employee benefits and as financing costs.
Acquisition
The company’s board of directors today approved an investment of RS 8.5 Crore for the acquisition of 85 Lakh shares from Apollo Gleneaagles PET-CT Private Limited (AGPCL) of the existing shareholder, Parkway Healthcare (Mauritius) PTE Limited, which represents AGPCL capital.
Read also: NSDL Q1 Results: Cons Pat jumps 15% JoJ to RS 90 crore despite a fall in turnover by 7%
(Disclaimer: recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)
#Apollo #Hospitals #Results #Cons #Pat #rises #JoJ #Crore #sales #rise